MMNFQ (MedMen Enterprises) EV-to-EBIT: 0.00 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedMen Enterprises EV-to-EBIT?

MedMen Enterprises MMNFQ -90.00% EV-to-EBIT is 0.00 as of Jul. 20, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MedMen Enterprises's Enterprise Value is $0.0 Mil. MedMen Enterprises's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-137.3 Mil. Therefore, MedMen Enterprises's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for MedMen Enterprises's EV-to-EBIT or its related term are showing as below:

MMNFQ's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 16
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MedMen Enterprises's Enterprise Value for the quarter that ended in Mar. 2023 was $-85.5 Mil. MedMen Enterprises's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-137.3 Mil. MedMen Enterprises's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 160.53%.

MedMen Enterprises  (OTCPK:MMNFQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MedMen Enterprises's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 ) =EBIT / Enterprise Value (Q: Mar. 2023 )
=-137.258/-85.5024708
=160.53 %

MedMen Enterprises's Enterprise Value for the quarter that ended in Mar. 2023 was $-85.5 Mil.
MedMen Enterprises's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises EV-to-EBIT Related Terms

MedMen Enterprises EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for MedMen Enterprises's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMen Enterprises EV-to-EBIT Chart

MedMen Enterprises Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,431.07 -2.67 -0.57 -2.16 0.05

MedMen Enterprises Quarterly Data
Apr18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 0.05 0.62 0.87 0.67

MMNFQ vs ZTS, VTRS, NBIX: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MedMen Enterprises's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMen Enterprises EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MedMen Enterprises's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MedMen Enterprises's EV-to-EBIT falls into.


MedMen Enterprises EV-to-EBIT Calculation

MedMen Enterprises's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-137.258
=0.00

MedMen Enterprises's current Enterprise Value is $0.0 Mil.
MedMen Enterprises's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
MedMen Enterprises (MMNFQ) has a EV-to-EBIT of 0.00 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MedMen Enterprises and its competitors.
Is MedMen Enterprises' EV-to-EBIT too high?
MedMen Enterprises' current EV-to-EBIT is 0.00.
How does MedMen Enterprises' EV-to-EBIT compare to ZTS and VTRS?
MedMen Enterprises' EV-to-EBIT of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.00, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MedMen Enterprises and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedMen Enterprises's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMen Enterprises stock overvalued right now?
MedMen Enterprises (MMNFQ) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MedMen Enterprises (MMNFQ), the current EV-to-EBIT is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMen Enterprises Business Description

Address 8740 S Sepulveda Boulevard, Suite 105, Los Angeles, CA, USA, 90045
MedMen Enterprises Inc is a American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, the company has MedMen and LuxLyte brands offering cannabis in consumer-preferred product forms for medical and recreational use. It produces and curates the consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs.